Literature DB >> 30070416

Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.

Christian Gagliardi1, Federico Perfetto2, Massimiliano Lorenzini1,3, Alessandra Ferlini4, Fabrizio Salvi5, Agnese Milandri1, Cristina Candida Quarta6, Giulia Taborchi2, Simone Bartolini2, Sabrina Frusconi2, Raffaele Martone2, Michele Mario Cinelli1, Serena Foffi1, Maria Letizia Bacchi Reggiani1, Gioele Fabbri1, Paolo Cataldo1, Francesco Cappelli2, Claudio Rapezzi1.   

Abstract

AIMS: Cardiac amyloidosis remains a great challenge for the cardiologist. One of the three main aetiological forms, transthyretin-related hereditary amyloidosis (ATTRm), can present with several phenotypes, depending mainly on the specific mutation. We aimed to characterize the phenotype of patients with ATTRm due to Ile68Leu mutation, comparing them to patients with wild-type transthyretin amyloidosis (ATTRwt). METHODS AND
RESULTS: Data of 67 Ile68Leu ATTRm patients from two Italian referral centres (Bologna and Florence) were retrospectively analysed and compared to those of 82 ATTRwt patients. Fifty-five unaffected mutation carriers were also analysed. Cumulative disease onset was 50% at age 71. A total of 56/67 (84%) patients had a predominantly cardiac phenotype at presentation with concentric increase in left ventricular wall thickness [median 17 mm], and normal or near normal left ventricular ejection fraction (79% of patients). Low QRS voltages were present only in 29% of patients but voltage/mass ratio was low (0.5). Carpal tunnel syndrome was noted in 43%. The overall phenotypic profile was similar to ATTRwt but Ile68Leu ATTRm patients typically presented younger (median 71 vs. 78 years) and were more likely to have (mild) symptomatic neurological involvement (19% vs. 2%). Male prevalence was 44% in unaffected mutation carriers and 78% in affected patients. Age-adjusted survival was comparable between groups.
CONCLUSIONS: Ile68Leu ATTRm is a cause of familial amyloidotic cardiomyopathy endemic in central-northern Italy and presents as hypertrophic/restrictive cardiomyopathy quite similar to ATTRwt. Male preponderance is present in affected patients but not in unaffected mutation carriers. Age-adjusted survival is similar to ATTRwt.
© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.

Entities:  

Keywords:  Amyloidosis; Cardiomyopathy; Heart failure; Transthyretin

Mesh:

Year:  2018        PMID: 30070416     DOI: 10.1002/ejhf.1285

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  8 in total

1.  Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review.

Authors:  Pranav Chandrashekar; Laith Alhuneafat; Meghan Mannello; Lana Al-Rashdan; Morris M Kim; Jason Dungu; Kevin Alexander; Ahmad Masri
Journal:  Circ Genom Precis Med       Date:  2021-08-31

2.  Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area.

Authors:  Massimo Russo; Luca Gentile; Vincenzo Di Stefano; Gianluca Di Bella; Fabio Minutoli; Antonio Toscano; Filippo Brighina; Giuseppe Vita; Anna Mazzeo
Journal:  Brain Sci       Date:  2021-04-27

Review 3.  Highlights in heart failure.

Authors:  Daniela Tomasoni; Marianna Adamo; Carlo Mario Lombardi; Marco Metra
Journal:  ESC Heart Fail       Date:  2019-12

Review 4.  Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.

Authors:  Hiroyuki Yamamoto; Tomoki Yokochi
Journal:  ESC Heart Fail       Date:  2019-09-25

5.  Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy.

Authors:  Shan He; Zhuang Tian; Hongzhi Guan; Jian Li; Quan Fang; Shuyang Zhang
Journal:  Orphanet J Rare Dis       Date:  2019-11-12       Impact factor: 4.123

6.  Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis.

Authors:  Antonella De Lillo; Gita A Pathak; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Federico Perfetto; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Clin Epigenetics       Date:  2020-11-17       Impact factor: 6.551

7.  Established and candidate transthyretin amyloidosis variants identified in the Saudi population by data mining.

Authors:  Mohamed Abouelhoda; Dania Mohty; Islam Alayary; Brian F Meyer; Stefan T Arold; Bahaa M Fadel; Dorota Monies
Journal:  Hum Genomics       Date:  2021-08-11       Impact factor: 4.639

Review 8.  Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.

Authors:  Federico Perfetto; Mattia Zampieri; Carlo Fumagalli; Marco Allinovi; Francesco Cappelli
Journal:  Intern Emerg Med       Date:  2022-03-24       Impact factor: 5.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.